Anatoli Mawanda
ID: UNCST-2024-R015927
|
Cytological Follow-Up & Molecular Exploration of HPV In HIV+ And
HIV- Individuals Post-LEEP
REFNo: HS7427ES
To investigate cytological changes and molecular profiles of HPV variants in individuals post-LEEP,
distinguishing between those with and without HIV.
To compare post-LEEP cytological alterations in HIV+ and HIV- cohorts,
To identify the genotypes associated with HPV persistence or recurrence in two cohorts.
To explore the correlation between HIV status and HPV recurrence post-LEEP.
|
Uganda |
2026-05-14 13:41:48 |
2029-05-14 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Tomos Proffitt
ID: UNCST-2025-R020181
|
Western Rift Archaeology and Palaeoenvironment Project
(WRAP)
REFNo: SS5248ES
The overarching research question driving the WRAP project is: How and when did Homo adapt to the diverse ecotone environments of the Albertine Rift compared to the more open mosaic environments of the East African Rift?
The WRAP Project consists of five interlinked work packages (WP1-WP5; Table 2), each aimed at a specific objective:
• WP1- Conducting new field survey and excavations to identify and record new Plio-Pleistocene archaeological sites across the length of the Albertine Rift in Uganda.
• WP2- Reconstructing hominin behaviour in the Albertine Rift during the Pleistocene.
• WP3- Refining the chronology of the hominin cultural and fossil record of the Albertine Rift in Uganda by applying new dating techniques.
• WP4- Reconstructing the Pleistocene environments both synchronically and diachronically in the Albertine Rift of Uganda.
• WP5- Synthesising and comparing the Pleistocene archaeological record of the Albertine Rift into the broader understanding of hominin evolution, environmental and behavioural adaptations in the wider African continent.
|
UK |
2026-05-14 13:35:14 |
2029-05-14 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Nixon Niyonzima
ID: UNCST-2020-R014577
|
Clinical Effectiveness of Point-of-Care Breast Cancer Diagnostics in Ugandan Community Health Centers
REFNo: HS7522ES
To evaluate effectiveness of POC diagnostic evaluation administered by trained sonographers and cytopathologists, vs. standard care,To compare the sensitivity and specificity of the diagnostic kit to standard of care at the UCI,Development of an Automated FNA targeting System,
|
Uganda |
2026-05-14 13:33:40 |
2029-05-14 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Joseph Ngonzi
ID: UNCST-2019-R001579
|
AI-driven placental imaging tool to reduce adverse pregnancy outcomes through prediction of neonatal sepsis risk: Feasibility of clinical use
REFNo: HS7432ES
To evaluate the feasibility, usability, and acceptability of the RAISE tool for use at delivery. ,
|
Uganda |
2026-05-11 17:48:50 |
2029-05-11 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Crispus Natwijuka
ID: UNCST-2024-R016280
|
TESTING NRIMS VERSION 2
REFNo: SIR662ES
testing testing testing
|
Uganda |
2026-05-06 10:30:12 |
2029-05-06 |
Engineering and Technology |
Clinical Trial |
Non-degree Award |
|
Joseph Babigumira
ID: UNCST-2026-R023369
|
Behavioral Research for Informed Government Decision-Making Using Evidence (BRIDGE Trial)
REFNo: SS5072ES
Primary Objectives
1. To determine the relative effect of narrative framing (with citizen voice) versus technical framing of research evidence on senior policymakers' use of evidence, measured through citations in policy documents, requests for new analyses, and evidence-informed budget allocations.
2. To determine the relative effect of peer civil servant messengers versus external academic expert messengers on senior policymakers' use of research evidence, measured through the same behavioural outcomes.
3. To assess whether framing and messenger mechanisms interact, and which combination produces the greatest improvement across the four evidence-informed policymaking (EIPM) outcome domains: conceptual, attitudinal, procedural, and content.
Secondary Objectives
4. To identify through which cognitive, social, and procedural pathways framing and messenger interventions influence evidence use (e.g., comprehension, trust, integration into decision routines).
5. To assess how treatment effects vary by ministry (Finance, Trade, Energy, NPA), seniority (U1–U2 vs. U3–U4), gender, and baseline orientation to evidence.
6. To estimate the cost-effectiveness of each intervention variant per unit increase in evidence uptake, expressed as cost per 0.1 standard deviation increase in the Evidence Use Index (EUI).
7. To examine how electoral cycles, bureaucratic turnover, and patronage networks moderate the effectiveness of behavioural interventions during Uganda's 2025–2027 reform window.
Exploratory Objective
8. To assess what early signals suggest that increased evidence use contributes to improved economic policy outcomes (e.g., trade facilitation, domestic revenue mobilisation), recognising that attribution is limited within the 24-month trial horizon.
|
Uganda |
2026-04-30 18:43:15 |
2029-04-30 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
PROSSY SENYANGE
ID: UNCST-2025-R020541
|
PREVALENCE AND FACTORS ASSOCIATED WITH HIGH-RISK HPV POSITIVITY FOLLOWING TREATMENT FOR PRECANCEROUS CERVICAL LESIONS AMONG WOMEN LIVING WITH HIV AT MBARARA REGIONAL REFERRAL HOSPITAL.
REFNo: HS7368ES
General objective
To determine the prevalence and factors associated with high risk HPV positivity after treatment for precancerous lesions among women living with HIV at Mbarara Regional Referral Hospital
Specific Objectives
1. To determine the prevalence of high-risk HPV positivity after treatment for precancerous lesions among women living with HIV at Mbarara Regional Referral Hospital.
2. To determine the factors associated with high risk HPV positivity after treatment for precancerous lesions among women living with HIV at MRRH
|
Uganda |
2026-04-30 18:41:23 |
2029-04-30 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Mercy chelangat
ID: UNCST-2025-R017873
|
PREVALENCE OF HIGH ACUTE GLYCEMIC VARIABILITY, ITS ASSOCIATED FACTORS, AND 14 DAY MORTALITY AMONG PATIENTS ADMITTED WITH SEPSIS AT MBARARA REGIONAL REFERRAL HOSPITAL
REFNo: HS7303ES
General Objective
To determine the prevalence of high acute glycemic variability, its associated factors and 14-day mortality among patients admitted with sepsis at MRRH.
Specific Objectives
1. Determine the prevalence of high acute glycemic variability among patients admitted with sepsis at MRRH
2. To determine the factors associated with high acute glycemic variability among patients admitted with sepsis
3. To compare the 14-day mortality rates between sepsis patients with high versus normal acute glycemic variability
|
Uganda |
2026-04-30 18:40:37 |
2029-04-30 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Henry Ochola
ID:
|
MATERNAL EARLY WARNING SCORES AT MBARARA REGIONAL REFERRAL HOSPITAL: SCREENING PERFORMANCE VERSUS SHOCK INDEX, RISK FACTORS, AND EARLY OUTCOME INDICATORS
REFNo: HS7372ES
Main Objective
To evaluate the screening performance of Maternal Early Warning Scores compared with the Shock Index, and to identify associated risk factors and early maternal outcome indicators among women receiving obstetric care at Mbarara Regional Referral Hospital
Specific Objectives
1. To compare the proportion of women flagged high-risk by Maternal Early Warning Signs versus the Shock Index among women admitted at the maternity and gynaecology units at Mbarara Regional Referral Hospital.
2. To determine factors associated with being flagged high-risk at the index observation among women admitted at the maternity and gynaecology units at Mbarara Regional Referral Hospital, monitored with the Maternal Early Warning Signs chart.
3. To describe key process indicators (documentation completeness; guideline-timely escalation) and early outcomes (ICU admission; maternal near-miss; in-hospital mortality) among women admitted at the maternity and gynaecology units at Mbarara Regional Referral Hospital, monitored with the Maternal Early Warning Signs chart.
|
Uganda |
2026-04-30 18:39:12 |
2029-04-30 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Winnie Muyindike R
ID: UNCST-2021-R013558
|
Exploring low-level HIV viremia among individuals on dolutegravir in sub-Saharan Africa (Low-V Africa Study).
REFNo: HS7580ES
Aim 2: To elucidate pharmacologic, viral, and host factor determinants of the progression to VF among participants in the Low-V Africa Cohort. In doing so, we will also characterize the prevalence of these factors in the setting of pLLV in the Low-V Africa cohort. We will evaluate viral suppression and long-term persistence of LLV as secondary outcomes. Analyses will employ longitudinal modeling with repeated measures, as well as machine learning techniques. Aim 2a will assess adherence, as measured by TFV-DP levels from DBS, as a predictor of VF after pLLV. Aim 2b will assess HIV drug resistance, defined by GSS, as a predictor of VF after pLLV. Aim 2c will evaluate the impact of a hyperactive HIV-1 viral reservoir, identified with long-range plasma SGS and MIP-Seq, on the risk of VF after pLLV. Aim 2d will estimate the relative contributions of adherence, resistance, and the reservoir to VF after pLLV. ,Aim 1: To determine longitudinal outcomes of individuals with pLLV while on tenofovir/lamivudine/dolutegravir (TLD). We will enroll a cohort of 200 adults in Uganda with pLLV (Low-V Africa Cohort), defined as at least two consecutive VLs ranging 50-1,000 copies/mL while on TLD for at least 12 months. We will follow participants for 96 weeks and will collect plasma, dried blood spots (DBS), and peripheral blood mononuclear cells (PBMCs) at enrollment, as well as 24-, 48-, and 96-week study visits. Aim 1a will estimate the 96-week cumulative incidence of VF and poor clinical outcomes after pLLV. We will perform VL quantification at each study visit to determine whether participants progress to virologic failure (>1,000 copies/mL), achieve viral suppression (<50 copies/mL), or have persistence of LLV. As secondary outcomes, we will also estimate the cumulative incidence of opportunistic infections, hospitalization, and death. Aim 1b will determine the 96-week cumulative incidence of emergent HIV drug resistance and a hyperactive reservoir in PWH with pLLV. We will perform Sager sequencing of plasma specimens with VLs >500 copies/mL and long-range plasma single-genome HIV RNA sequencing (SGS) of plasma specimens with VLs ≤500 copies/mL at each time point, with genotyping of the protease/reverse transcriptase and integrase. We will perform matched integration site and proviral sequencing (MIP-Seq) on follow-up specimens with ongoing viremia, evidence of high-level ART adherence (by tenofovir diphosphate [TFV-DP] levels), and an active ART regimen (genotypic susceptibility score [GSS]≥2). Results will identify individuals with resistance versus a hyperactive reservoir in the setting of pLLV. ,
|
Uganda |
2026-04-30 18:38:20 |
2029-04-30 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|